MiR-760 overexpression promotes proliferation in ovarian cancer by downregulation of PHLPP2 expression
Ovarian cancer is one of the most lethal gynecologic malignancies worldwide and with poor prognosis and survival rate in women. Identifying sensitive and specific molecular in carcinogenesis may improve diagnostic and therapeutic strategies for this malignancy and achieve a better clinical outcome....
Saved in:
Published in | Gynecologic oncology Vol. 143; no. 3; pp. 655 - 663 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.12.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Ovarian cancer is one of the most lethal gynecologic malignancies worldwide and with poor prognosis and survival rate in women. Identifying sensitive and specific molecular in carcinogenesis may improve diagnostic and therapeutic strategies for this malignancy and achieve a better clinical outcome.
miR-760 expression in ovarian cancer cell lines and patient tissues were determined using Real-time PCR. 145 human ovarian cancer tissue samples were analyzed by RT-PCR to investigate the association between miR-760expression and the clinicopathological characteristics of ovarian cancer patients. Functional assays, such as MTT, anchorage-independent growth, colony formation and BRDU assay were used to determine the oncogenic role of miR-760 in human ovarian cancer progression. Furthermore, western blotting and luciferase assay were used to determine the mechanism of miR-760 promotes proliferation in ovarian cancer cells.
The expression of miR-760 was markedly upregulated in ovarian cancer cell lines and tissues, and high miR-760 expression was associated with an aggressive phenotype and poor prognosis with ovarian cancer patients. Upregulation of miR-760 promoted, whereas downregulation of miR-760 inhibited the proliferation of ovarian cancer cells in vitro. Additionally, we identified PHLPP2 as a direct target of miR-760, and silencing the expression of PHLPP2 is the essential biological function of miR-760 during ovarian cancer cell proliferation. Finally, we showed a significant correlation between miR-760 and PHLPP2 expression in ovarian cancer tissues.
Our findings suggest that miR-760 represents a potential onco-miR and participates in ovarian cancer carcinogenesis, which highlight its potential as a target for ovarian cancer therapy.
•MiR-760 was significantly upregulated in ovarian cancer.•Overexpressing miR-760 promoted aggressiveness of ovarian cancer.•MiR-760 promoted ovarian cancer aggressiveness by suppressing PGLPP2 expression. |
---|---|
AbstractList | Ovarian cancer is one of the most lethal gynecologic malignancies worldwide and with poor prognosis and survival rate in women. Identifying sensitive and specific molecular in carcinogenesis may improve diagnostic and therapeutic strategies for this malignancy and achieve a better clinical outcome.
miR-760 expression in ovarian cancer cell lines and patient tissues were determined using Real-time PCR. 145 human ovarian cancer tissue samples were analyzed by RT-PCR to investigate the association between miR-760expression and the clinicopathological characteristics of ovarian cancer patients. Functional assays, such as MTT, anchorage-independent growth, colony formation and BRDU assay were used to determine the oncogenic role of miR-760 in human ovarian cancer progression. Furthermore, western blotting and luciferase assay were used to determine the mechanism of miR-760 promotes proliferation in ovarian cancer cells.
The expression of miR-760 was markedly upregulated in ovarian cancer cell lines and tissues, and high miR-760 expression was associated with an aggressive phenotype and poor prognosis with ovarian cancer patients. Upregulation of miR-760 promoted, whereas downregulation of miR-760 inhibited the proliferation of ovarian cancer cells in vitro. Additionally, we identified PHLPP2 as a direct target of miR-760, and silencing the expression of PHLPP2 is the essential biological function of miR-760 during ovarian cancer cell proliferation. Finally, we showed a significant correlation between miR-760 and PHLPP2 expression in ovarian cancer tissues.
Our findings suggest that miR-760 represents a potential onco-miR and participates in ovarian cancer carcinogenesis, which highlight its potential as a target for ovarian cancer therapy. Ovarian cancer is one of the most lethal gynecologic malignancies worldwide and with poor prognosis and survival rate in women. Identifying sensitive and specific molecular in carcinogenesis may improve diagnostic and therapeutic strategies for this malignancy and achieve a better clinical outcome. miR-760 expression in ovarian cancer cell lines and patient tissues were determined using Real-time PCR. 145 human ovarian cancer tissue samples were analyzed by RT-PCR to investigate the association between miR-760expression and the clinicopathological characteristics of ovarian cancer patients. Functional assays, such as MTT, anchorage-independent growth, colony formation and BRDU assay were used to determine the oncogenic role of miR-760 in human ovarian cancer progression. Furthermore, western blotting and luciferase assay were used to determine the mechanism of miR-760 promotes proliferation in ovarian cancer cells. The expression of miR-760 was markedly upregulated in ovarian cancer cell lines and tissues, and high miR-760 expression was associated with an aggressive phenotype and poor prognosis with ovarian cancer patients. Upregulation of miR-760 promoted, whereas downregulation of miR-760 inhibited the proliferation of ovarian cancer cells in vitro. Additionally, we identified PHLPP2 as a direct target of miR-760, and silencing the expression of PHLPP2 is the essential biological function of miR-760 during ovarian cancer cell proliferation. Finally, we showed a significant correlation between miR-760 and PHLPP2 expression in ovarian cancer tissues. Our findings suggest that miR-760 represents a potential onco-miR and participates in ovarian cancer carcinogenesis, which highlight its potential as a target for ovarian cancer therapy. •MiR-760 was significantly upregulated in ovarian cancer.•Overexpressing miR-760 promoted aggressiveness of ovarian cancer.•MiR-760 promoted ovarian cancer aggressiveness by suppressing PGLPP2 expression. Abstract Objective Ovarian cancer is one of the most lethal gynecologic malignancies worldwide and with poor prognosis and survival rate in women. Identifying sensitive and specific molecular in carcinogenesis may improve diagnostic and therapeutic strategies for this malignancy and achieve a better clinical outcome. Methods miR-760 expression in ovarian cancer cell lines and patient tissues were determined using Real-time PCR. 145 human ovarian cancer tissue samples were analyzed by RT-PCR to investigate the association between miR-760expression and the clinicopathological characteristics of ovarian cancer patients. Functional assays, such as MTT, anchorage-independent growth, colony formation and BRDU assay were used to determine the oncogenic role of miR-760 in human ovarian cancer progression. Furthermore, western blotting and luciferase assay were used to determine the mechanism of miR-760 promotes proliferation in ovarian cancer cells. Result The expression of miR-760 was markedly upregulated in ovarian cancer cell lines and tissues, and high miR-760 expression was associated with an aggressive phenotype and poor prognosis with ovarian cancer patients. Upregulation of miR-760 promoted, whereas downregulation of miR-760 inhibited the proliferation of ovarian cancer cells in vitro. Additionally, we identified PHLPP2 as a direct target of miR-760, and silencing the expression of PHLPP2 is the essential biological function of miR-760 during ovarian cancer cell proliferation. Finally, we showed a significant correlation between miR-760 and PHLPP2 expression in ovarian cancer tissues. Conclusion Our findings suggest that miR-760 represents a potential onco-miR and participates in ovarian cancer carcinogenesis, which highlight its potential as a target for ovarian cancer therapy. |
Author | He, Shanyang You, Zeshan Deng, Yalan Yao, Shuzhong Ye, Zhanying Liu, Jun Liao, Yanbin |
Author_xml | – sequence: 1 givenname: Yanbin surname: Liao fullname: Liao, Yanbin organization: Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510700, PR China – sequence: 2 givenname: Yalan surname: Deng fullname: Deng, Yalan organization: Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510700, PR China – sequence: 3 givenname: Jun surname: Liu fullname: Liu, Jun organization: Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510700, PR China – sequence: 4 givenname: Zhanying surname: Ye fullname: Ye, Zhanying organization: Department of Function, Hospital of Dongkeng, Dongguan 523451,PR China – sequence: 5 givenname: Zeshan surname: You fullname: You, Zeshan organization: Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510700, PR China – sequence: 6 givenname: Shuzhong surname: Yao fullname: Yao, Shuzhong organization: Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510700, PR China – sequence: 7 givenname: Shanyang surname: He fullname: He, Shanyang email: hsy5g777@sina.com organization: Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510700, PR China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27726922$$D View this record in MEDLINE/PubMed |
BookMark | eNqFke1qFDEUhoNU7LZ6BYLMDcx4ksxkJoiClGqFFRc_wH8hk5wpWWeTJZmtzt2b6VqEgvZXvt7nPTnvOSMnPngk5DmFigIVL7fVfD37ULF8qEBWQOERWVGQTSm6Rp6QFYCEsmNNd0rOUtoCAAfKnpBT1rZMSMZWZPjoPpetgCLcYMRf-4gpueCLfQy7MGFaNqMbMOppuXY-C3V02hdGe4Ox6OfChp8-4vVhPGrCUGyu1psNK_76PSWPBz0mfPZnPSff3l1-vbgq15_ef7h4uy5NLcRUGqt7Dpz1LUgrrUEhuW21NU3N626wLe9RtHLotdEDz4-MN8JaajqKdRbwc_Li6Ls_9Du0ah_dTsdZ3TWcBfIoMDGkFHFQxk23_56idqOioJZw1VbdhquWcBVIlcPNLL_H3tn_n3p9pDD3feMwqmQc5uysi2gmZYN7gH9zjzej887o8QfOmLbhEH2OVFGVmAL1ZRn6MnMqOK0pfM8Gr_5t8GD5337zv6o |
CitedBy_id | crossref_primary_10_1177_11769343211041379 crossref_primary_10_1155_2022_2960773 crossref_primary_10_1002_cam4_2866 crossref_primary_10_1016_j_bbrc_2019_03_009 crossref_primary_10_3892_mmr_2019_10008 crossref_primary_10_1016_j_canlet_2024_217357 crossref_primary_10_1007_s11010_024_05004_1 crossref_primary_10_1101_gad_339317_120 crossref_primary_10_3892_mmr_2017_7814 crossref_primary_10_1016_j_lfs_2020_118337 crossref_primary_10_1016_j_omto_2022_03_004 crossref_primary_10_2147_CMAR_S256670 crossref_primary_10_1074_jbc_M117_809913 crossref_primary_10_2147_CMAR_S352308 crossref_primary_10_1016_j_clinsp_2024_100391 crossref_primary_10_3748_wjg_v25_i45_6619 crossref_primary_10_1080_15548627_2020_1733262 crossref_primary_10_1109_TCBB_2019_2933205 crossref_primary_10_1016_j_placenta_2022_01_013 crossref_primary_10_1111_1759_7714_13196 crossref_primary_10_3389_fphar_2019_01700 crossref_primary_10_3390_cancers13112690 crossref_primary_10_1016_j_ygyno_2017_12_018 crossref_primary_10_3390_ijms22020627 crossref_primary_10_3892_mmr_2019_10775 crossref_primary_10_4103_aja_aja_20_20 crossref_primary_10_1093_bib_bbab264 crossref_primary_10_1016_j_prp_2021_153420 crossref_primary_10_3390_genes13112054 crossref_primary_10_3892_ol_2018_9546 crossref_primary_10_1002_jcb_29540 crossref_primary_10_1007_s10620_021_06876_9 crossref_primary_10_1016_j_gene_2020_144903 crossref_primary_10_3389_fonc_2020_01084 crossref_primary_10_3389_fmed_2022_923275 crossref_primary_10_3233_CBM_190091 crossref_primary_10_1016_j_biopha_2018_01_076 crossref_primary_10_1016_j_gene_2020_144648 crossref_primary_10_1111_jcmm_14071 crossref_primary_10_1038_s41420_022_01236_6 crossref_primary_10_2147_OTT_S240022 crossref_primary_10_3390_cancers13051085 crossref_primary_10_1177_1533033819853237 crossref_primary_10_1007_s11356_017_1138_0 crossref_primary_10_1186_s13046_018_0757_8 crossref_primary_10_1016_j_envpol_2021_117213 |
Cites_doi | 10.3892/br.2013.109 10.1146/annurev-pharmtox-011112-140338 10.2174/18715206113139990116 10.1097/AOG.0000000000000854 10.1007/s13277-016-4900-x 10.2174/1568009611313030001 10.1007/s10549-012-2035-3 10.1158/1078-0432.CCR-12-3186 10.1016/j.biopha.2014.11.028 10.1007/s00125-011-2116-6 10.1007/s13277-015-3445-8 10.1097/IGC.0000000000000007 10.1158/0008-5472.CAN-13-0297 10.1053/j.gastro.2011.10.026 10.1158/2159-8290.CD-ND2013-013 10.1111/j.1471-4159.2010.06609.x 10.18632/oncotarget.6848 10.1016/S0092-8674(04)00045-5 10.1038/nature02871 10.1016/j.molmed.2014.06.005 10.3802/jgo.2015.26.2.155 10.1038/sj.onc.1209100 10.1016/j.devcel.2006.09.009 10.1016/j.molcel.2007.02.017 10.1158/1078-0432.CCR-13-0244 10.1158/1078-0432.CCR-07-4054 10.1016/j.fertnstert.2014.04.024 10.3322/caac.21262 10.1007/s13277-014-2790-3 10.14348/molcells.2014.0157 10.1186/s13048-015-0162-2 10.1046/j.1525-1438.2001.11(suppl.1)sup1003.x 10.1158/1078-0432.CCR-14-2829 10.1007/978-3-319-17121-0_55 10.1016/j.ygyno.2014.07.103 10.1186/s13046-016-0307-1 10.1186/1757-2215-5-8 10.1186/s12885-015-1711-1 |
ContentType | Journal Article |
Copyright | 2016 Copyright © 2016. Published by Elsevier Inc. |
Copyright_xml | – notice: 2016 – notice: Copyright © 2016. Published by Elsevier Inc. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM |
DOI | 10.1016/j.ygyno.2016.09.010 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1095-6859 |
EndPage | 663 |
ExternalDocumentID | 27726922 10_1016_j_ygyno_2016_09_010 S009082581631410X 1_s2_0_S009082581631410X |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29I 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFGL ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DM4 DU5 EBS EFBJH EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IH2 IHE J1W K-O KOM L7B LG5 M29 M41 MO0 N9A O-L O9- OAUVE OQ. OZT P-8 P-9 P2P PC. PH~ Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SES SEW SPCBC SSH SSZ T5K UDS UHS UV1 WUQ X7M XPP Z5R ZGI ZMT ZU3 ZXP ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG LCYCR AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM |
ID | FETCH-LOGICAL-c466t-cdab3032b709d9dce693d7adc54348fd73be679fbacaf36932356dd1c81e448f3 |
IEDL.DBID | .~1 |
ISSN | 0090-8258 |
IngestDate | Thu Apr 03 07:02:54 EDT 2025 Thu Apr 24 23:10:16 EDT 2025 Tue Jul 01 03:07:44 EDT 2025 Fri Feb 23 02:31:06 EST 2024 Tue Feb 25 20:12:37 EST 2025 Tue Aug 26 16:32:53 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | PHLPP2 Proliferation miR-760 Ovarian cancer |
Language | English |
License | Copyright © 2016. Published by Elsevier Inc. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c466t-cdab3032b709d9dce693d7adc54348fd73be679fbacaf36932356dd1c81e448f3 |
PMID | 27726922 |
PageCount | 9 |
ParticipantIDs | pubmed_primary_27726922 crossref_citationtrail_10_1016_j_ygyno_2016_09_010 crossref_primary_10_1016_j_ygyno_2016_09_010 elsevier_sciencedirect_doi_10_1016_j_ygyno_2016_09_010 elsevier_clinicalkeyesjournals_1_s2_0_S009082581631410X elsevier_clinicalkey_doi_10_1016_j_ygyno_2016_09_010 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-12-01 |
PublicationDateYYYYMMDD | 2016-12-01 |
PublicationDate_xml | – month: 12 year: 2016 text: 2016-12-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Gynecologic oncology |
PublicationTitleAlternate | Gynecol Oncol |
PublicationYear | 2016 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Menon, Jacobs (bb0020) 2001; 11 Yang, Gu, Zhou, Xiang, Chen (bb0130) 2013; 1 Li, Shi, Ling, Wang, Liu, Wang (bb0065) 2015; 36 Lee, Kim, Bae (bb0145) 2014; 37 Torre, Bray, Siegel, Ferlay, Lortet-Tieulent, Jemal (bb0005) 2015; 65 Testa, Tsichlis (bb0170) 2005; 24 Jiang (bb0180) 2013; 13 Baley, Li (bb0050) 2012; 5 Chang, Bristow (bb0010) 2015; 26 Liu, Qin, Hou, Huang (bb0075) 2015; 36 Lv, Yang, Wang, Xie, Hu, Ye (bb0195) 2015; 15 Li, Zhang, Song, Liao, Jiang (bb0110) 2008; 14 Zhou, Yu, Wang, Li, Jin, Lei (bb0080) 2015; 10 Li, Fang, Liu, Yang (bb0060) 2015; 8 Huang, Pan, Jin, Li, Zhang, Yang (bb0085) 2015; 21 Hayes, Peruzzi, Lawler (bb0125) 2014; 20 Lv, Fu, Shi, Xia, Ji, Xu (bb0140) 2015; 69 Iwaya, Fukagawa, Suzuki, Takahashi, Sawada, Ishibashi (bb0135) 2013; 19 Rajala, Kanan, Anderson (bb0155) 2016; 854 Yan, Jiang, Meng, Xiu, Zong (bb0070) 2016; 35 Cai, Fang, Huang, Li, Yuan, Yang (bb0095) 2013; 73 Wright, Chen, Tergas, Patankar, Burke, Hou (bb0015) 2015; 125 Newton, Trotman (bb0150) 2014; 54 Ambros (bb0045) 2004; 431 Liao, Li, Wang, Wang, He, Ye (bb0100) 2013; 19 Brognard, Sierecki, Gao, Newton (bb0185) 2007; 25 Bartel (bb0040) 2004; 116 Gill, Alex, Navgeet (bb0115) 2016 Santarpia, Qi, Stemke-Hale, Wang, Young, Booser (bb0090) 2012; 134 Kanan, Matsumoto, Song, Sokolov, Anderson, Rajala (bb0165) 2010; 113 Imbar, Eisenberg (bb0055) 2014; 101 Kumar, Bakkum-Gamez, Weaver, McGree, Cliby (bb0025) 2014; 135 Andreozzi, Procopio, Greco, Mannino, Miele, Raciti (bb0160) 2011; 54 Amate, Huchon, Dessapt, Bensaid, Medioni, Le Frere Belda (bb0035) 2013; 23 Smith, Wen, Stevens, Liu, Wang, Gao (bb0190) 2016 Kloosterman, Plasterk (bb0120) 2006; 11 Sylvester, Ayoub (bb0175) 2013; 13 Nitsche, Edderkaoui, Moore, Eibl, Kasahara, Treger (bb0105) 2012; 142 Bender (bb0030) 2013; 3 Lv (10.1016/j.ygyno.2016.09.010_bb0140) 2015; 69 Newton (10.1016/j.ygyno.2016.09.010_bb0150) 2014; 54 Smith (10.1016/j.ygyno.2016.09.010_bb0190) 2016 Bartel (10.1016/j.ygyno.2016.09.010_bb0040) 2004; 116 Lee (10.1016/j.ygyno.2016.09.010_bb0145) 2014; 37 Cai (10.1016/j.ygyno.2016.09.010_bb0095) 2013; 73 Ambros (10.1016/j.ygyno.2016.09.010_bb0045) 2004; 431 Li (10.1016/j.ygyno.2016.09.010_bb0065) 2015; 36 Hayes (10.1016/j.ygyno.2016.09.010_bb0125) 2014; 20 Menon (10.1016/j.ygyno.2016.09.010_bb0020) 2001; 11 Rajala (10.1016/j.ygyno.2016.09.010_bb0155) 2016; 854 Kloosterman (10.1016/j.ygyno.2016.09.010_bb0120) 2006; 11 Jiang (10.1016/j.ygyno.2016.09.010_bb0180) 2013; 13 Andreozzi (10.1016/j.ygyno.2016.09.010_bb0160) 2011; 54 Lv (10.1016/j.ygyno.2016.09.010_bb0195) 2015; 15 Huang (10.1016/j.ygyno.2016.09.010_bb0085) 2015; 21 Nitsche (10.1016/j.ygyno.2016.09.010_bb0105) 2012; 142 Sylvester (10.1016/j.ygyno.2016.09.010_bb0175) 2013; 13 Torre (10.1016/j.ygyno.2016.09.010_bb0005) 2015; 65 Liu (10.1016/j.ygyno.2016.09.010_bb0075) 2015; 36 Testa (10.1016/j.ygyno.2016.09.010_bb0170) 2005; 24 Iwaya (10.1016/j.ygyno.2016.09.010_bb0135) 2013; 19 Zhou (10.1016/j.ygyno.2016.09.010_bb0080) 2015; 10 Santarpia (10.1016/j.ygyno.2016.09.010_bb0090) 2012; 134 Brognard (10.1016/j.ygyno.2016.09.010_bb0185) 2007; 25 Baley (10.1016/j.ygyno.2016.09.010_bb0050) 2012; 5 Li (10.1016/j.ygyno.2016.09.010_bb0060) 2015; 8 Amate (10.1016/j.ygyno.2016.09.010_bb0035) 2013; 23 Liao (10.1016/j.ygyno.2016.09.010_bb0100) 2013; 19 Yan (10.1016/j.ygyno.2016.09.010_bb0070) 2016; 35 Wright (10.1016/j.ygyno.2016.09.010_bb0015) 2015; 125 Kanan (10.1016/j.ygyno.2016.09.010_bb0165) 2010; 113 Chang (10.1016/j.ygyno.2016.09.010_bb0010) 2015; 26 Bender (10.1016/j.ygyno.2016.09.010_bb0030) 2013; 3 Li (10.1016/j.ygyno.2016.09.010_bb0110) 2008; 14 Kumar (10.1016/j.ygyno.2016.09.010_bb0025) 2014; 135 Yang (10.1016/j.ygyno.2016.09.010_bb0130) 2013; 1 Gill (10.1016/j.ygyno.2016.09.010_bb0115) 2016 Imbar (10.1016/j.ygyno.2016.09.010_bb0055) 2014; 101 |
References_xml | – volume: 54 start-page: 1879 year: 2011 end-page: 1887 ident: bb0160 article-title: Increased levels of the Akt-specific phosphatase PH domain leucine-rich repeat protein phosphatase (PHLPP)-1 in obese participants are associated with insulin resistance publication-title: Diabetologia – volume: 73 start-page: 5402 year: 2013 end-page: 5415 ident: bb0095 article-title: miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer publication-title: Cancer Res. – volume: 116 start-page: 281 year: 2004 end-page: 297 ident: bb0040 article-title: MicroRNAs: genomics, biogenesis, mechanism, and function publication-title: Cell – volume: 65 start-page: 87 year: 2015 end-page: 108 ident: bb0005 article-title: Global cancer statistics, 2012 publication-title: CA Cancer J. Clin. – volume: 23 start-page: 1590 year: 2013 end-page: 1596 ident: bb0035 article-title: Ovarian cancer: sites of recurrence publication-title: Int. J. Gynecol. Cancer: Official Journal of the International Gynecological Cancer Society – year: 2016 ident: bb0190 article-title: PHLPP negatively regulates cell motility through inhibition of Akt activity and integrin expression in pancreatic cancer cells publication-title: Oncotarget – volume: 69 start-page: 162 year: 2015 end-page: 169 ident: bb0140 article-title: Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin publication-title: Biomedicine & Pharmacotherapy – volume: 19 start-page: 4662 year: 2013 end-page: 4672 ident: bb0100 article-title: microRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2 publication-title: Clin. Cancer Res.: An Official Journal of the American Association for Cancer Research – volume: 13 start-page: 1039 year: 2013 end-page: 1047 ident: bb0175 article-title: Tocotrienols target PI3K/Akt signaling in anti-breast cancer therapy publication-title: Anti Cancer Agents Med. Chem. – volume: 36 start-page: 1881 year: 2015 end-page: 1893 ident: bb0075 article-title: MicroRNA-17 promotes normal ovarian cancer cells to cancer stem cells development via suppression of the LKB1-p53-p21/WAF1 pathway publication-title: Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine – volume: 21 start-page: 3783 year: 2015 end-page: 3793 ident: bb0085 article-title: PHLPP2 downregulation contributes to lung carcinogenesis following B[ publication-title: Clin. Cancer Res.: An Official Journal of the American Association for Cancer Research – volume: 35 start-page: 31 year: 2016 ident: bb0070 article-title: MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression publication-title: J. Exp. Clin. Cancer Res.: CR. – volume: 14 start-page: 3319 year: 2008 end-page: 3326 ident: bb0110 article-title: Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival publication-title: Clin. Cancer Res. – volume: 101 start-page: 1524 year: 2014 end-page: 1530 ident: bb0055 article-title: Regulatory role of microRNAs in ovarian function publication-title: Fertil. Steril. – volume: 26 start-page: 155 year: 2015 ident: bb0010 article-title: Surgical technique of en bloc pelvic resection for advanced ovarian cancer publication-title: J. Gynecol. Oncol. – volume: 25 start-page: 917 year: 2007 end-page: 931 ident: bb0185 article-title: PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms publication-title: Mol. Cell – volume: 3 start-page: OF8 year: 2013 ident: bb0030 article-title: Trials show delayed recurrence in ovarian cancer publication-title: Cancer Discovery – volume: 1 start-page: 495 year: 2013 end-page: 498 ident: bb0130 article-title: Serum microRNAs: a new diagnostic method for colorectal cancer publication-title: Biomedical Reports – year: 2016 ident: bb0115 article-title: Missing link between microRNA and prostate cancer publication-title: Tumour Biol.: The Journal of the International Society for Oncodevelopmental Biology and Medicine – volume: 20 start-page: 460 year: 2014 end-page: 469 ident: bb0125 article-title: MicroRNAs in cancer: biomarkers, functions and therapy publication-title: Trends Mol. Med. – volume: 113 start-page: 477 year: 2010 end-page: 488 ident: bb0165 article-title: Serine/threonine kinase akt activation regulates the activity of retinal serine/threonine phosphatases, PHLPP and PHLPPL publication-title: J. Neurochem. – volume: 135 start-page: 19 year: 2014 end-page: 24 ident: bb0025 article-title: Impact of obesity on surgical and oncologic outcomes in ovarian cancer publication-title: Gynecol. Oncol. – volume: 36 start-page: 7277 year: 2015 end-page: 7283 ident: bb0065 article-title: MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL publication-title: Tumour Biol.: The Journal of the International Society for Oncodevelopmental Biology and Medicine – volume: 854 start-page: 419 year: 2016 end-page: 424 ident: bb0155 article-title: Photoreceptor neuroprotection: regulation of Akt activation through serine/threonine phosphatases, PHLPP and PHLPPL publication-title: Adv. Exp. Med. Biol. – volume: 13 start-page: 233 year: 2013 ident: bb0180 article-title: PI3K/AKT and mTOR/p70S6K1 signaling pathways in human cancer publication-title: Curr. Cancer Drug Targets – volume: 431 start-page: 350 year: 2004 end-page: 355 ident: bb0045 article-title: The functions of animal microRNAs publication-title: Nature – volume: 37 start-page: 620 year: 2014 end-page: 627 ident: bb0145 article-title: Upregulation of miR-760 and miR-186 is associated with replicative senescence in human lung fibroblast cells publication-title: Mol. Cell – volume: 10 year: 2015 ident: bb0080 article-title: Aberrant expression of PHLPP1 and PHLPP2 correlates with poor prognosis in patients with hypopharyngeal squamous cell carcinoma publication-title: PLoS One – volume: 24 start-page: 7391 year: 2005 end-page: 7393 ident: bb0170 article-title: AKT signaling in normal and malignant cells publication-title: Oncogene – volume: 134 start-page: 333 year: 2012 end-page: 343 ident: bb0090 article-title: Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers publication-title: Breast Cancer Res. Treat. – volume: 19 start-page: 6438 year: 2013 end-page: 6449 ident: bb0135 article-title: Contrasting expression patterns of histone mRNA and microRNA 760 in patients with gastric cancer publication-title: Clin. Cancer Res.: An Official Journal of the American Association for Cancer Research – volume: 15 start-page: 687 year: 2015 ident: bb0195 article-title: High PHLPP expression is associated with better prognosis in patients with resected lung adenocarcinoma publication-title: BMC Cancer – volume: 142 start-page: 377 year: 2012 end-page: 387 ident: bb0105 article-title: The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation publication-title: Gastroenterology – volume: 5 start-page: 8 year: 2012 ident: bb0050 article-title: MicroRNAs and ovarian function publication-title: Journal of Ovarian Research – volume: 11 start-page: 3 year: 2001 end-page: 6 ident: bb0020 article-title: Ovarian cancer screening in the general population: current status publication-title: International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society – volume: 125 start-page: 1345 year: 2015 end-page: 1352 ident: bb0015 article-title: Trends in relative survival for ovarian cancer from 1975 to 2011 publication-title: Obstet. Gynecol. – volume: 8 start-page: 51 year: 2015 ident: bb0060 article-title: MicroRNAs in ovarian function and disorders publication-title: Journal of Ovarian Research – volume: 11 start-page: 441 year: 2006 end-page: 450 ident: bb0120 article-title: The diverse functions of microRNAs in animal development and disease publication-title: Dev. Cell – volume: 54 start-page: 537 year: 2014 end-page: 558 ident: bb0150 article-title: Turning off AKT: PHLPP as a drug target publication-title: Annu. Rev. Pharmacol. Toxicol. – volume: 10 year: 2015 ident: 10.1016/j.ygyno.2016.09.010_bb0080 article-title: Aberrant expression of PHLPP1 and PHLPP2 correlates with poor prognosis in patients with hypopharyngeal squamous cell carcinoma publication-title: PLoS One – volume: 1 start-page: 495 year: 2013 ident: 10.1016/j.ygyno.2016.09.010_bb0130 article-title: Serum microRNAs: a new diagnostic method for colorectal cancer publication-title: Biomedical Reports doi: 10.3892/br.2013.109 – volume: 54 start-page: 537 year: 2014 ident: 10.1016/j.ygyno.2016.09.010_bb0150 article-title: Turning off AKT: PHLPP as a drug target publication-title: Annu. Rev. Pharmacol. Toxicol. doi: 10.1146/annurev-pharmtox-011112-140338 – volume: 13 start-page: 1039 year: 2013 ident: 10.1016/j.ygyno.2016.09.010_bb0175 article-title: Tocotrienols target PI3K/Akt signaling in anti-breast cancer therapy publication-title: Anti Cancer Agents Med. Chem. doi: 10.2174/18715206113139990116 – volume: 125 start-page: 1345 year: 2015 ident: 10.1016/j.ygyno.2016.09.010_bb0015 article-title: Trends in relative survival for ovarian cancer from 1975 to 2011 publication-title: Obstet. Gynecol. doi: 10.1097/AOG.0000000000000854 – year: 2016 ident: 10.1016/j.ygyno.2016.09.010_bb0115 article-title: Missing link between microRNA and prostate cancer publication-title: Tumour Biol.: The Journal of the International Society for Oncodevelopmental Biology and Medicine doi: 10.1007/s13277-016-4900-x – volume: 13 start-page: 233 year: 2013 ident: 10.1016/j.ygyno.2016.09.010_bb0180 article-title: PI3K/AKT and mTOR/p70S6K1 signaling pathways in human cancer publication-title: Curr. Cancer Drug Targets doi: 10.2174/1568009611313030001 – volume: 134 start-page: 333 year: 2012 ident: 10.1016/j.ygyno.2016.09.010_bb0090 article-title: Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-012-2035-3 – volume: 19 start-page: 6438 year: 2013 ident: 10.1016/j.ygyno.2016.09.010_bb0135 article-title: Contrasting expression patterns of histone mRNA and microRNA 760 in patients with gastric cancer publication-title: Clin. Cancer Res.: An Official Journal of the American Association for Cancer Research doi: 10.1158/1078-0432.CCR-12-3186 – volume: 69 start-page: 162 year: 2015 ident: 10.1016/j.ygyno.2016.09.010_bb0140 article-title: Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin publication-title: Biomedicine & Pharmacotherapy=Biomedecine & Pharmacotherapie doi: 10.1016/j.biopha.2014.11.028 – volume: 54 start-page: 1879 year: 2011 ident: 10.1016/j.ygyno.2016.09.010_bb0160 article-title: Increased levels of the Akt-specific phosphatase PH domain leucine-rich repeat protein phosphatase (PHLPP)-1 in obese participants are associated with insulin resistance publication-title: Diabetologia doi: 10.1007/s00125-011-2116-6 – volume: 36 start-page: 7277 year: 2015 ident: 10.1016/j.ygyno.2016.09.010_bb0065 article-title: MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL publication-title: Tumour Biol.: The Journal of the International Society for Oncodevelopmental Biology and Medicine doi: 10.1007/s13277-015-3445-8 – volume: 23 start-page: 1590 year: 2013 ident: 10.1016/j.ygyno.2016.09.010_bb0035 article-title: Ovarian cancer: sites of recurrence publication-title: Int. J. Gynecol. Cancer: Official Journal of the International Gynecological Cancer Society doi: 10.1097/IGC.0000000000000007 – volume: 73 start-page: 5402 year: 2013 ident: 10.1016/j.ygyno.2016.09.010_bb0095 article-title: miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-13-0297 – volume: 142 start-page: 377 year: 2012 ident: 10.1016/j.ygyno.2016.09.010_bb0105 article-title: The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation publication-title: Gastroenterology doi: 10.1053/j.gastro.2011.10.026 – volume: 3 start-page: OF8 year: 2013 ident: 10.1016/j.ygyno.2016.09.010_bb0030 article-title: Trials show delayed recurrence in ovarian cancer publication-title: Cancer Discovery doi: 10.1158/2159-8290.CD-ND2013-013 – volume: 113 start-page: 477 year: 2010 ident: 10.1016/j.ygyno.2016.09.010_bb0165 article-title: Serine/threonine kinase akt activation regulates the activity of retinal serine/threonine phosphatases, PHLPP and PHLPPL publication-title: J. Neurochem. doi: 10.1111/j.1471-4159.2010.06609.x – year: 2016 ident: 10.1016/j.ygyno.2016.09.010_bb0190 article-title: PHLPP negatively regulates cell motility through inhibition of Akt activity and integrin expression in pancreatic cancer cells publication-title: Oncotarget doi: 10.18632/oncotarget.6848 – volume: 116 start-page: 281 year: 2004 ident: 10.1016/j.ygyno.2016.09.010_bb0040 article-title: MicroRNAs: genomics, biogenesis, mechanism, and function publication-title: Cell doi: 10.1016/S0092-8674(04)00045-5 – volume: 431 start-page: 350 year: 2004 ident: 10.1016/j.ygyno.2016.09.010_bb0045 article-title: The functions of animal microRNAs publication-title: Nature doi: 10.1038/nature02871 – volume: 20 start-page: 460 year: 2014 ident: 10.1016/j.ygyno.2016.09.010_bb0125 article-title: MicroRNAs in cancer: biomarkers, functions and therapy publication-title: Trends Mol. Med. doi: 10.1016/j.molmed.2014.06.005 – volume: 26 start-page: 155 year: 2015 ident: 10.1016/j.ygyno.2016.09.010_bb0010 article-title: Surgical technique of en bloc pelvic resection for advanced ovarian cancer publication-title: J. Gynecol. Oncol. doi: 10.3802/jgo.2015.26.2.155 – volume: 24 start-page: 7391 year: 2005 ident: 10.1016/j.ygyno.2016.09.010_bb0170 article-title: AKT signaling in normal and malignant cells publication-title: Oncogene doi: 10.1038/sj.onc.1209100 – volume: 11 start-page: 441 year: 2006 ident: 10.1016/j.ygyno.2016.09.010_bb0120 article-title: The diverse functions of microRNAs in animal development and disease publication-title: Dev. Cell doi: 10.1016/j.devcel.2006.09.009 – volume: 25 start-page: 917 year: 2007 ident: 10.1016/j.ygyno.2016.09.010_bb0185 article-title: PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms publication-title: Mol. Cell doi: 10.1016/j.molcel.2007.02.017 – volume: 19 start-page: 4662 year: 2013 ident: 10.1016/j.ygyno.2016.09.010_bb0100 article-title: microRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2 publication-title: Clin. Cancer Res.: An Official Journal of the American Association for Cancer Research doi: 10.1158/1078-0432.CCR-13-0244 – volume: 14 start-page: 3319 year: 2008 ident: 10.1016/j.ygyno.2016.09.010_bb0110 article-title: Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-4054 – volume: 101 start-page: 1524 year: 2014 ident: 10.1016/j.ygyno.2016.09.010_bb0055 article-title: Regulatory role of microRNAs in ovarian function publication-title: Fertil. Steril. doi: 10.1016/j.fertnstert.2014.04.024 – volume: 65 start-page: 87 year: 2015 ident: 10.1016/j.ygyno.2016.09.010_bb0005 article-title: Global cancer statistics, 2012 publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21262 – volume: 36 start-page: 1881 year: 2015 ident: 10.1016/j.ygyno.2016.09.010_bb0075 article-title: MicroRNA-17 promotes normal ovarian cancer cells to cancer stem cells development via suppression of the LKB1-p53-p21/WAF1 pathway publication-title: Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine doi: 10.1007/s13277-014-2790-3 – volume: 37 start-page: 620 year: 2014 ident: 10.1016/j.ygyno.2016.09.010_bb0145 article-title: Upregulation of miR-760 and miR-186 is associated with replicative senescence in human lung fibroblast cells publication-title: Mol. Cell doi: 10.14348/molcells.2014.0157 – volume: 8 start-page: 51 year: 2015 ident: 10.1016/j.ygyno.2016.09.010_bb0060 article-title: MicroRNAs in ovarian function and disorders publication-title: Journal of Ovarian Research doi: 10.1186/s13048-015-0162-2 – volume: 11 start-page: 3 issue: Suppl. 1 year: 2001 ident: 10.1016/j.ygyno.2016.09.010_bb0020 article-title: Ovarian cancer screening in the general population: current status publication-title: International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society doi: 10.1046/j.1525-1438.2001.11(suppl.1)sup1003.x – volume: 21 start-page: 3783 year: 2015 ident: 10.1016/j.ygyno.2016.09.010_bb0085 article-title: PHLPP2 downregulation contributes to lung carcinogenesis following B[a]P/B[a]PDE exposure publication-title: Clin. Cancer Res.: An Official Journal of the American Association for Cancer Research doi: 10.1158/1078-0432.CCR-14-2829 – volume: 854 start-page: 419 year: 2016 ident: 10.1016/j.ygyno.2016.09.010_bb0155 article-title: Photoreceptor neuroprotection: regulation of Akt activation through serine/threonine phosphatases, PHLPP and PHLPPL publication-title: Adv. Exp. Med. Biol. doi: 10.1007/978-3-319-17121-0_55 – volume: 135 start-page: 19 year: 2014 ident: 10.1016/j.ygyno.2016.09.010_bb0025 article-title: Impact of obesity on surgical and oncologic outcomes in ovarian cancer publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2014.07.103 – volume: 35 start-page: 31 year: 2016 ident: 10.1016/j.ygyno.2016.09.010_bb0070 article-title: MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression publication-title: J. Exp. Clin. Cancer Res.: CR. doi: 10.1186/s13046-016-0307-1 – volume: 5 start-page: 8 year: 2012 ident: 10.1016/j.ygyno.2016.09.010_bb0050 article-title: MicroRNAs and ovarian function publication-title: Journal of Ovarian Research doi: 10.1186/1757-2215-5-8 – volume: 15 start-page: 687 year: 2015 ident: 10.1016/j.ygyno.2016.09.010_bb0195 article-title: High PHLPP expression is associated with better prognosis in patients with resected lung adenocarcinoma publication-title: BMC Cancer doi: 10.1186/s12885-015-1711-1 |
SSID | ssj0003012 |
Score | 2.4338017 |
Snippet | Ovarian cancer is one of the most lethal gynecologic malignancies worldwide and with poor prognosis and survival rate in women. Identifying sensitive and... Abstract Objective Ovarian cancer is one of the most lethal gynecologic malignancies worldwide and with poor prognosis and survival rate in women. Identifying... |
SourceID | pubmed crossref elsevier |
SourceType | Index Database Enrichment Source Publisher |
StartPage | 655 |
SubjectTerms | Blotting, Western Carcinogenesis - genetics Cell Line, Tumor Cell Proliferation - genetics Down-Regulation Female Gene Expression Regulation, Neoplastic HEK293 Cells Hematology, Oncology and Palliative Medicine Humans In Vitro Techniques MicroRNAs - genetics miR-760 Obstetrics and Gynecology Ovarian cancer Ovarian Neoplasms - genetics Ovarian Neoplasms - metabolism PHLPP2 Phosphoprotein Phosphatases - metabolism Proliferation Real-Time Polymerase Chain Reaction Up-Regulation |
Title | MiR-760 overexpression promotes proliferation in ovarian cancer by downregulation of PHLPP2 expression |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S009082581631410X https://www.clinicalkey.es/playcontent/1-s2.0-S009082581631410X https://dx.doi.org/10.1016/j.ygyno.2016.09.010 https://www.ncbi.nlm.nih.gov/pubmed/27726922 |
Volume | 143 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swELcQk6a9oI0x6BjID3tcRmIndvxYVaBCKaoQiL5Z8RcqQqFqi0Rf-Nvnc5wytKlIPOXLdpLz5Xyn_H53CP0kqeJUVyaxzPoAxZUuqQS1CVPBGyZUhBpLwwvWv87PxsV4A_VaLgzAKqPtb2x6sNbxzFGU5tF0MgGOL5TrLkrvUQBYcQwM9pyDlv9-foF5eAVuMoYHynRRtpmHAsZrebusgQGYsZDsFGi0a1env5aek89oK_qMuNs81he0Yett9HEY_4p_RW44uUw4SzHAMe1ThLbWeBqgdnYOO_cAYQmzgCe1b-hD5KrGGuZ8htUSGx-Nz5q69NDmweFR_3w0IvhlvB10fXJ81esnsX5ConPGFok2lfIrFFE8FUYYbZmghldGA520dIZTZRkXTlW6ctRfJLRgxmS6zKyP2hz9hjbrh9ruIey4LY2PPTJe5XmutKKuEN73IJnNylJkHURauUkdk4tDjYt72aLI7mQQtgRhy1RIL-wO-rXqNG1ya6xvnrcTIlvaqDd00tv-9d34_7rZefxY5zKTcyJT-Y9CdRBb9Xylk2_fcrfRl9VrER_EMEHI9_cOuY8-wVEDpPmBNhezR3vg3aGFOgz6fog-dE8H_QvYDi5vBn8Ah9YLxA |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIkEviGdZnj7AjdDESez4wAEB1ZbuVivUSnsz8ataVKWrzVawF_4Uf5Cx42xBoEVC6i1KPI7yeTyeUb6ZAXhBU8VzXZvEMosBiqtcUovcJkwFb5jmIvRYGh-x4UnxcVpOt-BHnwvjaZXR9nc2PVjreGcvork3n818jq9v111W6FF4suI0MisP7eorxm3tm4P3uMgvKd3_cPxumMTWAokuGFsm2tQKjTdVPBVGGG2ZyA2vjfaZlpUzPFeWceFUrWuX40Oal8yYTFeZxYDG5TjvNbheoLnwbRNef7_kleCO6UqUhxztsupLHQVS2ep01fiUw4yF6qo-b3fjcfjLWbd_G25FJ5W87XC4A1u2uQs3xvE3_D1w49mnhLOUeP6n_Ra5tA2ZB26fbf3FmefMhGUnswYHYkxeN0R7JVsQtSIGw_-FPY3dw8i5I5PhaDKh5HK--3ByJag-gO3mvLEPgThuK4PBTsbroiiUVrkrBTo7NLNZVYlsALTHTepYzdw31TiTPW3tiwxgSw-2TIVEsAfwai0074p5bB5e9Asi-zxVtKwSD5vNYvxvYraN1qGVmWypTOUfGjwAtpb8bRP8-5W7nb6sP4ti1MQEpY_-d8rncHN4PB7J0cHR4WPY8U86Fs8T2F4uLuxT9MWW6lnQfQKfr3qz_QSHS0cr |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MiR-760+overexpression+promotes+proliferation+in+ovarian+cancer+by+downregulation+of+PHLPP2+expression&rft.jtitle=Gynecologic+oncology&rft.au=Liao%2C+Yanbin&rft.au=Deng%2C+Yalan&rft.au=Liu%2C+Jun&rft.au=Ye%2C+Zhanying&rft.date=2016-12-01&rft.issn=0090-8258&rft_id=info:doi/10.1016%2Fj.ygyno.2016.09.010&rft.externalDBID=ECK1-s2.0-S009082581631410X&rft.externalDocID=1_s2_0_S009082581631410X |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-8258&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-8258&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-8258&client=summon |